Ruben Sevillano's Contact Details

Ruben Sevillano's Company Details

ALGENEX S.L

Tres Cantos, Community of Madrid, Spain • 30 Employees
Research

We are experts in developing novel sub-unit vaccinesOur initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio® - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platform's potential. CrisBio® also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner.Our current portfolio comprises 6 vaccines across livestock species. Proof of concepts have been generated in > 20 additional vaccine antigensValue through collaborationsOur go to market strategy is inherently linked to collaborations. We offer:• Development of tailor-made baculovirus vectors optimized for industrial production.• Proof-of-concept studies to validate the production of recombinant proteins in CrisBio®.• Supply of recombinant proteins produced in CrisBio® through license agreements.• Development of proprietary portfolios.Algenex is led by an internationally experienced management team, that is supported by a well-balanced Strategic Advisory Board that combines industry and investment experience.